Noradrenaline in mood and anxiety disorders:
basic and clinical studies

by
Brunello N, Blier P, Judd LL, Mendlewicz J,
Nelson CJ, Souery D, Zohar J, Racagni G.
a, Center of Neuropharmacology,
University of Milan, Italy
b, Department of Pharmaceutical Sciences,
University of Modena and Reggio Emilia, Italy.
Int Clin Psychopharmacol. 2003 Jul;18(4):191-202


ABSTRACT

The neurotransmitter noradrenaline is known to be involved in a range of physiological and psychological processes, and dysfunctions of this neurotransmitter system have been implicated in a range of psychiatric disorders. However, the clinical utility of targeting the noradrenergic system in the treatment of such disorders has been somewhat overshadowed by the availability of agents selective for the serotonin system. A number of antidepressants with increased, but varying, selectivity for the noradrenergic system have become available in recent years, including mirtazapine, bupropion and, most recently, the first truly selective noradrenaline reuptake inhibitor, reboxetine. This review brings together current thinking on the role of noradrenaline in the aetiology and therapy of mood disorders to encourage a rational, evidence-based approach to the treatment of such disorders, and to provide suggestions and guidelines for future research in the area.

Noradrenaline and depression
Noradrenergic antidepressants
Reboxetine and psychomotor function
Noradrenaline, reboxetine and depression
Depression, antidepressants and noradrenaline



Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family